Eric Venker - Sep 19, 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
President & Immunovant CEO
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Stock symbol
ROIV
Transactions as of
Sep 19, 2025
Transactions value $
-$19,509,637
Form type
4
Date filed
9/23/2025, 09:00 PM
Previous filing
Aug 22, 2025
Next filing
Oct 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Venker Eric President & Immunovant CEO C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 2025-09-23 0001801917

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $3.85M +1M +60.47% $3.85 2.65M Sep 19, 2025 Direct
transaction ROIV Common Shares Sale -$10.2M -684K -25.77% $14.95 1.97M Sep 19, 2025 Direct F1
transaction ROIV Common Shares Options Exercise $1.78M +462K +23.47% $3.85 2.43M Sep 22, 2025 Direct
transaction ROIV Common Shares Options Exercise $385K +100K +4.11% $3.85 2.53M Sep 22, 2025 Direct
transaction ROIV Common Shares Sale -$4.74M -316K -12.49% $14.99 2.22M Sep 22, 2025 Direct F1
transaction ROIV Common Shares Sale -$1.5M -100K -4.51% $15.01 2.12M Sep 22, 2025 Direct F2
transaction ROIV Common Shares Sale -$9.06M -611K -28.88% $14.83 1.5M Sep 23, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -1M -12.44% $0.00 7.04M Sep 19, 2025 Common Stock 1M $3.85 Direct F3
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -462K -6.57% $0.00 6.58M Sep 22, 2025 Common Stock 462K $3.85 Direct F3
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -100K -1.52% $0.00 6.48M Sep 22, 2025 Common Stock 100K $3.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024.
F3 Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).